Kensey Nash Looking At Smaller Angio-Seal To Boost Market Share
This article was originally published in The Gray Sheet
Kensey Nash is predicting that the U.S. launch in January of a 6 Fr version of its Angio-Seal hemostatic puncture closure device will give the company a leg up on competitors Datascope (VasoSeal) and Perclose (ProStar and TechStar).
You may also be interested in...
St. Jude's $167 mil. cash acquisition of marketing and manufacturing rights to Kensey Nash's Angio-Seal hemostatic puncture closure device from Tyco International would "more than double" sales into the cardiology cath lab by St. Jude's Daig division and add 60 to its sales and marketing staff, the firm states.
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. But how to know what variants need a limited study and which one need a big one will be an ongoing challenge, NIH's Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.